Bortezomib increases the sensitivity of multiple myeloma cells to the cytotoxicity of gamma-delta T cells

      Multiple myeloma (MM) is by far not curable plasma cell malignancy, although the new drugs such as bortezomib, achieve an attractive results. This study is to investigate the possible synergistic cytotoxic effects against MM cells between γδT cells and bortezomib, and its mechanism, with the aim of providing a novel therapeutic strategy for MM.
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to Cytotherapy
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect